


### AMENDMENTS TO THE SPECIFICATION

Please replace paragraphs [0030] and [0031] with the following amended paragraphs:

[0030] A particularly preferred embodiment of the present invention relates to the compounds of formula (Ib)



wherein

V is O, S, -CH<sub>2</sub>-, -CH=CH-, or -C≡C-;

W is COO or SO<sub>2</sub>;

p is an integer from 0 to 7, with the proviso that p is not 0 when V is O or S;

A<sub>11</sub> is H, lower-alkyl, or hydroxy-lower-alkyl and

A<sub>12</sub> is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl, or

A<sub>11</sub> and A<sub>12</sub> bond together to form  $[-A^1-A^2-] - \underline{A^{11}-A^{12}}$ , wherein  $[-A^1-A^2-] - \underline{A^{11}-A^{12}}$  is lower-alkylene;

A<sub>13</sub> and A<sub>14</sub> are each hydrogen or bond together to form  $[-A^3-A^4-] - \underline{A^{13}-A^{14}}$ , wherein  $[-A^3-A^4-] - \underline{A^{13}-A^{14}}$  is -(CH<sub>2</sub>)<sub>2-5</sub>;

A<sub>15</sub> is lower-alkyl; and

A<sub>16</sub> is halogen or trifluoromethyl.

[0031] Also ~~preferred~~ preferred are pharmaceutically acceptable salts and esters of the compounds of formula (Ib).